Each film-coated tablet contains: Trimetazidine (as HCl) BP 35 mg (in modified release form).
Trimetazidine is a metabolic agent, a specific and selective inhibitor of enzymes of the fatty acids β-oxidation: The 3 ketoacyl CoA thiolase (3-KAT). This inhibition of β-oxidant allows a recoupling of glycolysis and an increase in glucose oxidation for better energy production under ischemic conditions.
Pharmacology: Pharmacokinetics: After oral administration, maximum concentration is found on average, 5 hours after taking the tablet. Over 24 hours, the plasma concentration remains at levels >75% of the maximum concentration for 1 hour. Steady state is reached by the 60th hour, at the latest. Trimetazidine is eliminated primarily in the urine mainly in the unchanged form.
It is used in the treatment of angina pectoris and in ischemia of neurosensorial tissues in Meniere's disease.
One (1) tablet in the morning and (1) in the evening during mealtime. Or as prescribed by the physician.
Hypersensitivity to any of the ingredients.
The drug is not a curative treatment for angina attacks, nor initial treatment for unstable angina pectoris, it is not a treatment for myocardial infarction. In the event of angina attack, inform the doctor.
Use in Lactation: Trimetazidine is not recommended on lactating mothers.
Rare cases of gastrointestinal disorders (nausea and vomiting).
Co-administration with MAOI's, impaired renal and hepatic function.
Store at temperatures not exceeding 30ºC.
C01EB15 - trimetazidine ; Belongs to the class of other cardiac preparations.